AU2006270315A1 - Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate - Google Patents

Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate Download PDF

Info

Publication number
AU2006270315A1
AU2006270315A1 AU2006270315A AU2006270315A AU2006270315A1 AU 2006270315 A1 AU2006270315 A1 AU 2006270315A1 AU 2006270315 A AU2006270315 A AU 2006270315A AU 2006270315 A AU2006270315 A AU 2006270315A AU 2006270315 A1 AU2006270315 A1 AU 2006270315A1
Authority
AU
Australia
Prior art keywords
composition according
dvs
dosage unit
superbioavailable
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006270315A
Other languages
English (en)
Inventor
Christopher Richard Diorio
Mahdi B. Fawzi
Syed M. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2006270315A1 publication Critical patent/AU2006270315A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006270315A 2005-07-15 2006-07-13 Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate Abandoned AU2006270315A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15
US60/699,623 2005-07-15
PCT/US2006/027106 WO2007011619A2 (en) 2005-07-15 2006-07-13 Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate

Publications (1)

Publication Number Publication Date
AU2006270315A1 true AU2006270315A1 (en) 2007-01-25

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006270315A Abandoned AU2006270315A1 (en) 2005-07-15 2006-07-13 Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate

Country Status (20)

Country Link
US (1) US20070014859A1 (https=)
EP (1) EP1904040A2 (https=)
JP (1) JP2009501233A (https=)
KR (1) KR20080025405A (https=)
CN (1) CN101247791A (https=)
AR (1) AR054833A1 (https=)
AU (1) AU2006270315A1 (https=)
BR (1) BRPI0613484A2 (https=)
CA (1) CA2612960A1 (https=)
CR (1) CR9626A (https=)
EC (1) ECSP088106A (https=)
GT (1) GT200600307A (https=)
IL (1) IL188313A0 (https=)
MX (1) MX2008000666A (https=)
NO (1) NO20080088L (https=)
PE (1) PE20070192A1 (https=)
RU (1) RU2007148195A (https=)
SV (1) SV2008002612A (https=)
TW (1) TW200740427A (https=)
WO (1) WO2007011619A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629609A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0722303A2 (pt) * 2007-12-10 2014-04-22 Wyeth Llc O-desmatil-venlafaxina para tratar transtorno depressivo maior
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
WO2007011619A2 (en) 2007-01-25
MX2008000666A (es) 2008-03-13
US20070014859A1 (en) 2007-01-18
SV2008002612A (es) 2008-08-29
EP1904040A2 (en) 2008-04-02
BRPI0613484A2 (pt) 2016-11-16
CR9626A (es) 2008-04-10
KR20080025405A (ko) 2008-03-20
NO20080088L (no) 2008-04-02
CA2612960A1 (en) 2007-01-25
GT200600307A (es) 2008-04-24
WO2007011619A3 (en) 2007-06-21
JP2009501233A (ja) 2009-01-15
RU2007148195A (ru) 2009-08-20
PE20070192A1 (es) 2007-03-16
CN101247791A (zh) 2008-08-20
ECSP088106A (es) 2008-02-20
IL188313A0 (en) 2008-04-13
TW200740427A (en) 2007-11-01
AR054833A1 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
US20070014859A1 (en) Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
US8987333B2 (en) Composition and method for treating neurological disease
CA2808912C (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20130115298A2 (en) Extended release compositions comprising as active compound venlafaxine hydrochloride
CA2453263C (en) Pharmaceutical compositions containing terbinafine and use thereof
CN101843590A (zh) 缓释文拉法辛药物制剂
US20050175698A1 (en) Multiparticulate O-desmethylvenlafaxine salts and uses thereof
MX2013010920A (es) Metodos y composiciones para el tratamiento de transtorno por deficit de atencion.
JP2012516299A (ja) 有機化合物のガレヌス製剤
JP7048770B2 (ja) ピリドスチグミンを含む持続放出組成物
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
RU2435573C2 (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
WO2007112574A1 (en) Extended release composition of venlafaxine
WO2014096982A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2003082261A1 (en) Extended release venlafaxine formulations
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
CN101756987A (zh) 一种愈创木酚甘油醚、伪麻黄碱和右美沙芬的复方缓释制剂
US11096945B2 (en) Pharmaceutical compositions of linagliptin and process for preparation thereof
US20240315962A1 (en) Extended release compositions comprising pyridostigmine
MXPA06008933A (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
CA3210988A1 (en) Extended-release compositions comprising atomoxetine
US20140112995A1 (en) Multi-layered, multiple unit pharmaceutical compositions
CN101766620A (zh) 一种美芬氯雷伪麻缓释制剂及其制备方法
CA2758657A1 (en) Controlled release formulations of tolterodine and process of manufacturing
HK1103517B (en) Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application